Raymond James & Associates Reduces Stock Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Raymond James & Associates lessened its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH – Get Rating) by 3.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 60,430 shares of the company’s stock after selling 1,992 shares during the quarter. Raymond James & Associates owned 0.12% of Prestige Consumer Healthcare worth $3,783,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of PBH. New York State Common Retirement Fund raised its holdings in Prestige Consumer Healthcare by 27.3% in the third quarter. New York State Common Retirement Fund now owns 45,866 shares of the company’s stock valued at $2,286,000 after acquiring an additional 9,825 shares in the last quarter. PDT Partners LLC acquired a new position in shares of Prestige Consumer Healthcare during the 3rd quarter worth $329,000. Congress Asset Management Co. MA grew its stake in shares of Prestige Consumer Healthcare by 14.1% during the 4th quarter. Congress Asset Management Co. MA now owns 76,300 shares of the company’s stock worth $4,776,000 after purchasing an additional 9,447 shares during the period. Centiva Capital LP acquired a new stake in Prestige Consumer Healthcare in the 3rd quarter valued at about $200,000. Finally, Ergoteles LLC acquired a new stake in Prestige Consumer Healthcare in the 3rd quarter valued at about $297,000. Hedge funds and other institutional investors own 99.98% of the company’s stock.

Analyst Ratings Changes

PBH has been the topic of several recent analyst reports. Royal Bank of Canada cut their price objective on shares of Prestige Consumer Healthcare from $107.00 to $104.00 and set a “sector perform” rating on the stock in a report on Friday, March 17th. Oppenheimer reduced their price objective on Prestige Consumer Healthcare from $72.00 to $71.00 and set an “outperform” rating on the stock in a research note on Friday, February 17th. StockNews.com initiated coverage on Prestige Consumer Healthcare in a research note on Thursday, May 18th. They issued a “buy” rating on the stock. Finally, TheStreet cut shares of Prestige Consumer Healthcare from a “b+” rating to a “c+” rating in a research note on Thursday, May 4th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $79.25.

Prestige Consumer Healthcare Stock Down 1.6 %

PBH opened at $58.35 on Friday. The business has a 50 day moving average price of $61.43 and a 200 day moving average price of $61.65. Prestige Consumer Healthcare Inc. has a twelve month low of $48.51 and a twelve month high of $67.45. The company has a debt-to-equity ratio of 0.93, a quick ratio of 1.43 and a current ratio of 2.44. The firm has a market cap of $2.90 billion, a P/E ratio of -35.30, a price-to-earnings-growth ratio of 1.75 and a beta of 0.56.

Prestige Consumer Healthcare (NYSE:PBH – Get Rating) last released its quarterly earnings data on Thursday, May 4th. The company reported $1.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.04 by $0.03. Prestige Consumer Healthcare had a positive return on equity of 13.38% and a negative net margin of 7.30%. The business had revenue of $285.90 million for the quarter, compared to analysts’ expectations of $280.58 million. During the same period in the previous year, the business posted $0.91 earnings per share. Prestige Consumer Healthcare’s quarterly revenue was up 7.1% on a year-over-year basis. Research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.3 EPS for the current year.

Prestige Consumer Healthcare Company Profile

(Get Rating)

Prestige Consumer Healthcare, Inc engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody’s, Beano, Boudreaux’s Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden’s, Monistat, Nix, Pedia-Lax, and Summer’s Eve.